Tolvaptan in the Treatment of the Syndrome of Inappropriate Anti-Diuretic Hormone in Cancer Patients

Only 2patients were discharged, while the other patients died.Conclusion: The use of tolvaptan in the treatment of SIADH-induced hypotonic euvolemic hyponatremia providedan effective correction in serum sodium concentration, and improved the symptoms associated with hyponatremia.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objectives: This study aimed to reveal the therapeutic efficacy and side effects of tolvaptan use in patients with hypotonic euvolemic hyponatremia caused by syndrome of inappropriate anti-diuretic hormone (SIADH) in our oncologyclinic.

📊

Key Findings & Data:Herein is presented the first real-life data on the use of tolvaptan in hyponatremia observed in cancer patients inTurkey to the researchers’ knowledge.Methods: Clinically euvolemic patients who had serum osmolality 100 mOsm/kg,urine sodium concentration >40 mmol/L and were diagnosed with SIADH, were scanned via electronic data.

💡

Conclusion & Impact:Only 2patients were discharged, while the other patients died.Conclusion: The use of tolvaptan in the treatment of SIADH-induced hypotonic euvolemic hyponatremia providedan effective correction in serum sodium concentration, and improved the symptoms associated with hyponatremia.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Objectives: This study aimed to reveal the therapeutic efficacy and side effects of tolvaptan use in patients with hypotonic euvolemic hyponatremia caused by syndrome of inappropriate anti-diuretic hormone (SIADH) in our oncologyclinic. Herein is presented the first real-life data on the use of tolvaptan in hyponatremia observed in cancer patients inTurkey to the researchers’ knowledge.Methods: Clinically euvolemic patients who had serum osmolality 100 mOsm/kg,urine sodium concentration >40 mmol/L and were diagnosed with SIADH, were scanned via electronic data. In treatment, tolvaptan 15 mg/day was administered for 3 days.Results: Hypotonic euvolemic hyponatremia due to SIADH was diagnosed in 24 patients (16 males, 8 females) whofollowed up for malignancy. The median sodium value of the patients before tolvaptan treatment was 121.5 mEq/L.The median sodium concentrations in the 3 days of treatment were 126.0 mEq/L, 132.0 mEq/L and 137.0 mEq/L, respectively. In 6 patients, adverse effects were observed; none of them stopped or paused treatment, however. Only 2patients were discharged, while the other patients died.Conclusion: The use of tolvaptan in the treatment of SIADH-induced hypotonic euvolemic hyponatremia providedan effective correction in serum sodium concentration, and improved the symptoms associated with hyponatremia.

🔖

Cite This Article

ÇUBUKÇU, E., OCAK, B., ŞAHİN, A. B., DELİGONUL, A., ORHAN, S. O., EVRENSEL, T., DAKİKİ, B., CANER, B., ERTAŞ, H. (2022). Tolvaptan in the Treatment of the Syndrome of Inappropriate Anti-Diuretic Hormone in Cancer Patients. Eurasian Journal of Medical Investigation, Cilt: 4 - Sayı: 4, 490–494. https://ajindex.com/articles/508681

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (14)

Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 2012;59:222–8
Grohé C, Berardi R, Burst V. Hyponatraemia--SIADH in lung cancer diagnostic and treatment algorithms. Crit Rev Oncol Hematol 2015;96:1–8
Petereit C, Zaba O, Teber I, Lüders H, Grohé C. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan. BMC Pulm Med 2013;13:55
Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957;23:529–42
Gennari FJ. Current concepts. Serum osmolality. Uses and limitations. N Engl J Med 1984;310:102–5
Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342:1581–9
Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother 2003;37:1694–702
Hansen O, Sørensen P, Hansen KH. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10- year period. Lung Cancer 2010;68:111–4
Chute JP, Taylor E, Williams J, Kaye F, Venzon D, Johnson BE. A metabolic study of patients with lung cancer and hyponatremia of malignancy. Clin Cancer Res 2006;12:888–96
Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist 2012;17:756–65
Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA. Medical costs of abnormal serum sodium levels. J Am Soc Nephrol 2008;19:764–70 12. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099–112
Salahudeen AK, Ali N, George M, Lahoti A, Palla S. Tolvaptan in hospitalized cancer patients with hyponatremia: a doubleblind, randomized, placebo-controlled clinical trial on efficacy and safety. Cancer 2014;120:744–51
Burst V, Grundmann F, Kubacki T, Greenberg A, Rudolf D, Salahudeen A, et al. Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study. Support Care Cancer 2017;25:2275–83
De Las Peñas R, Ponce S, Henao F, Camps Herrero C, Carcereny E, Escobar Álvarez Y, et al. SIADH-related hyponatremia in hospital day care units: clinical